PLEOPHARMA TO PRESENT SURVEY DATA ON CANNABIS WITHDRAWAL IN WOMEN SEEKING CANNABIS CESSATION PleoPharma, Inc. October 22

PleoPharma said a survey of 146 women who had tried to stop, reduce or pause cannabis use found 90% reported at least one withdrawal symptom; 61% said symptoms began within 24 hours, including 12% within three hours. The survey found 84% had sought medical help and about two-thirds were interested in medication-assisted treatment. Separately, national survey data from 2021–2024 showed moderate-to-severe cannabis use disorder increased approximately twofold among women ages 35–49 and sevenfold among women 50 and older; the findings were presented at The Menopause Society’s 2026 Annual Meeting.

Analysis

The survey supports a hypothesis of unmet need, not evidence that PP-01 works or that a market of investable size exists. Its online, self-selected sample of 146 women limits prevalence and demand inference; company-sponsored findings should be discounted until replicated and linked to treatment-seeking rates, diagnosis, and willingness to pay. The key value inflection is clinical: efficacy on withdrawal and abstinence, safety, durability, and a credible regulatory path. If those clear, PleoPharma could compete for attention and capital with addiction-medicine and behavioral-health developers; the indirect effect on cannabis producers would likely be small unless treatment meaningfully increases cessation at scale. Near term, the conference presentation is unlikely to justify a sector-level trade. Over 1–3 months, watch for trial design, enrollment, and financing disclosures; over 6–18 months, clinical readouts and regulatory feedback matter more than survey interest. The contrarian risk is that high reported symptom burden does not translate into sustained medication uptake: cannabis-use behavior, heterogeneous patients, and adherence may constrain commercial adoption. PP-01 is described as investigational, and the supplied data provide no public ticker or independently verified financial impact.

Key Decisions for Investors

• No trade on the survey alone. PleoPharma has no ticker in the supplied mapping, and the evidence is not a clinical efficacy readout.
• Set an alert for PP-01 trial design, enrollment, safety, and efficacy disclosures; verify whether endpoints measure sustained abstinence or only short-term withdrawal relief, and whether an FDA interaction clarifies the development path.
• Before assigning commercial value, seek independent evidence on diagnosed cannabis use disorder, treatment-seeking conversion, payer coverage, and patient willingness to use medication; the survey does not establish these.
• Falsify the bullish unmet-need thesis if subsequent controlled studies fail to show clinically meaningful benefit, safety or adherence impairs use, or trial delays/financing needs materially weaken development prospects.